Malaysia Intranasal Drug And Vaccine Delivery Market Size & Outlook

The intranasal drug and vaccine delivery market in Malaysia is expected to reach a projected revenue of US$ 1,745.1 million by 2030. A compound annual growth rate of 6.4% is expected of Malaysia intranasal drug and vaccine delivery market from 2024 to 2030.
Revenue, 2023 (US$M)
$1,129.0
Forecast, 2030 (US$M)
$1,745.1
CAGR, 2024 - 2030
6.4%
Report Coverage
Malaysia

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Malaysia intranasal drug and vaccine delivery market, 2018-2030 (US$M)

Malaysia intranasal drug and vaccine delivery market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Related Markets

Malaysia intranasal drug and vaccine delivery market highlights

  • The Malaysia intranasal drug and vaccine delivery market generated a revenue of USD 1,129.0 million in 2023 and is expected to reach USD 1,745.1 million by 2030.
  • The Malaysia market is expected to grow at a CAGR of 6.4% from 2024 to 2030.
  • In terms of segment, liquid delivery device was the largest revenue generating product in 2023.
  • Pressurized Metered Dose Inhaler is the most lucrative product segment registering the fastest growth during the forecast period.


Intranasal drug and vaccine delivery market data book summary

Market revenue in 2023USD 1,129.0 million
Market revenue in 2030USD 1,745.1 million
Growth rate6.4% (CAGR from 2023 to 2030)
Largest segmentLiquid delivery device
Fastest growing segmentPressurized Metered Dose Inhaler
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPowder delivery device, Liquid Delivery Device, Pressurized Metered Dose Inhaler
Key market players worldwideGSK PLC ADR, Teva Pharmaceutical Industries Ltd, AptarGroup Inc, UCB SA, Teleflex Inc, 3M Co, OptiNose Inc, Bespak, Intersect ENT


Other key industry trends

  • In terms of revenue, Malaysia accounted for 1.7% of the global intranasal drug and vaccine delivery market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China intranasal drug and vaccine delivery market is projected to lead the regional market in terms of revenue in 2030.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 5,992.1 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Intranasal Drug And Vaccine Delivery Market Companies

Name Profile # Employees HQ Website
Intersect ENT View profile 251-500 Menlo Park, California, United States, North America http://www.intersectent.com
Bespak View profile 501-1000 Lynn, Norfolk, United Kingdom, Europe http://www.bespak.com
OptiNose Inc View profile 132 1020 Stony Hill Road, Suite 300, Yardley, PA, United States, 19067 https://www.optinose.com
Teleflex Inc View profile 14500 550 East Swedesford Road, Suite 400, Wayne, PA, United States, 19087 https://www.teleflex.com
UCB SA View profile 9083 Allee de la Recherche, 60, Brussels, Belgium, B-1070 https://www.ucb.com
AptarGroup Inc View profile 13800 265 Exchange Drive, Suite 301, Crystal Lake, IL, United States, 60014 https://www.aptar.com
GSK PLC ADR View profile 70200 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS https://www.gsk.com
3M Co View profile 85000 3M Center, St. Paul, MN, United States, 55144 https://www.3m.com
Teva Pharmaceutical Industries Ltd View profile 37851 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 https://www.tevapharm.com

Malaysia intranasal drug and vaccine delivery market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intranasal drug and vaccine delivery market will help companies and investors design strategic landscapes.


Liquid delivery device was the largest segment with a revenue share of 40.81% in 2023. Horizon Databook has segmented the Malaysia intranasal drug and vaccine delivery market based on powder delivery device, liquid delivery device, pressurized metered dose inhaler covering the revenue growth of each sub-segment from 2018 to 2030.


Malaysia has a dual healthcare system in which both the public and private players are present. The public healthcare system is understaffed but there is constant increase in investments by the Malaysian government. The private sector medical facilities are generally used by the upper-class affluent citizens.

Healthcare coverage is provided by both public and private players. Malaysia imports medical consumables from countries like Japan, Germany, America, and South Korea.

Reasons to subscribe to Malaysia intranasal drug and vaccine delivery market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Malaysia intranasal drug and vaccine delivery market databook

  • Our clientele includes a mix of intranasal drug and vaccine delivery market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Malaysia intranasal drug and vaccine delivery market , including forecasts for subscribers. This country databook contains high-level insights into Malaysia intranasal drug and vaccine delivery market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Malaysia intranasal drug and vaccine delivery market size, by dosage, 2018-2030 (US$M)

Malaysia Intranasal Drug And Vaccine Delivery Market Outlook Share, 2023 & 2030 (US$M)

Malaysia intranasal drug and vaccine delivery market size, by dosage, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online